Table 1.

Randomized clinical studies of imatinib in advanced or metastatic GIST—beyond 1 year of treatment

Abbreviations: AE, adverse event; CI, confidence interval; CR, complete response; DOR, duration of response; GIST, gastrointestinal stromal tumors; KIT+, KIT-positive; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; TTP, time to progression; TTR, time to response.